Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Potential Screening Market Size, Customized Forecasting and Analysis with Executive and Consultant Guides 2021 to 2025
“Cancer Gene Profiling changes cancer diagnosis and treatment. New science creating new market opportunities with regularity. Market affected by COVID-19 Pandemic....”
Cancer gene panels and genomic profiling are quickly changing the diagnosis and treatment of cancer. The market is moving out of a specialized niche and going mainstream as oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer, however the COVID-19 pandemic has impacted the market. Find out how in this new report edition.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School